SUBSCRIBE
SUBSCRIBE
News   Business

Biogen Idec, Inc. (Massachusetts) Reports First Quarter 2010 Results TYSABRI(R) Revenues Increase 32% Year over Year

April 20, 2010 | 
1 min read
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.
Earnings
Biogen
MORE ON THIS TOPIC
Cooperation concept. Vector of a businessman and a businesswoman connecting the bridge with a missing part
GLP-1s
Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute
March 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Dashed line from pills isolated on white
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Vertex Terminates 20 in Reorganization Push
March 9, 2026
 · 
32 min read
 · 
BioSpace Editorial Staff
Brain tumor medical poster. Cancer, metastasis or benign in the human head or in the nerves, pituitary gland, pineal gland, and membranes that cover the surface of the brain 3D vector illustration
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
March 6, 2026
 · 
1 min read
 · 
Annalee Armstrong